APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live and Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Live and Attenuated Vaccine Industry Growth and Trends Forecast to 2032

20 December 2025105 pages

Choose your research edition.

Industry ResearchLive and Attenuated Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Live and Attenuated Vaccine Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Live and Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live and Attenuated Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Live and Attenuated Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Live and Attenuated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live and Attenuated Vaccine include Sanofi, Johnson & Johnson, Merck & Co., Pfizer, Inc, GlaxoSmithKline, Serum Institute, MedImmune, LLC, Emergent BioSolutions, Inc. and CSL Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Live and Attenuated Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Live and Attenuated Vaccine market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Live and Attenuated Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Live and Attenuated Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Live and Attenuated Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Live and Attenuated Vaccine Market by Company

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer, Inc

GlaxoSmithKline

Serum Institute

MedImmune, LLC

Emergent BioSolutions, Inc.

CSL Limited

Astellas Pharma Inc

Live and Attenuated Vaccine Segment by Type

Pediatric Vaccine

Adult Vaccines

Live and Attenuated Vaccine Segment by Application

Clinics

Diagnostic Centers

Hospitals

Research Institute

Others

Live and Attenuated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live and Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live and Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live and Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live and Attenuated Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Live and Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Pediatric Vaccine Table 2. Major Company of Adult Vaccines Table 3. Global Live and Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 5. Global Live and Attenuated Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Live and Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Live and Attenuated Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Live and Attenuated Vaccine Price by Type (2021-2026) & (US$/unit) Table 9. Global Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 10. Global Live and Attenuated Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Live and Attenuated Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Live and Attenuated Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Live and Attenuated Vaccine Price by Type (2027-2032) & (US$/unit) Table 14. North America Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 15. North America Live and Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 17. Europe Live and Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Live and Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 21. Latin America Live and Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Live and Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Live and Attenuated Vaccine Industry Trends Table 25. Live and Attenuated Vaccine Industry Drivers Table 26. Live and Attenuated Vaccine Industry Opportunities and Challenges Table 27. Live and Attenuated Vaccine Industry Restraints Table 28. Global Live and Attenuated Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Live and Attenuated Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Live and Attenuated Vaccine Sales by Company (2021-2026) & (k units) Table 31. Global Live and Attenuated Vaccine Sales Share by Company (2021-2026) Table 32. Global Live and Attenuated Vaccine Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Live and Attenuated Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Live and Attenuated Vaccine Major Company Production Sites and Headquarters Table 35. Global Live and Attenuated Vaccine Company, Product Type & Application Table 36. Global Live and Attenuated Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Live and Attenuated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Live and Attenuated Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Live and Attenuated Vaccine Sales by Region (2021-2026) & (k units) Table 41. Global Live and Attenuated Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Live and Attenuated Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Live and Attenuated Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Live and Attenuated Vaccine Sales by Region (2027-2032) & (k units) Table 46. Global Live and Attenuated Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Live and Attenuated Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Live and Attenuated Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Live and Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 52. Global Live and Attenuated Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Live and Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Live and Attenuated Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Live and Attenuated Vaccine Price by Application (2021-2026) & (US$/unit) Table 56. Global Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 57. Global Live and Attenuated Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Live and Attenuated Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Live and Attenuated Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Live and Attenuated Vaccine Price by Application (2027-2032) & (US$/unit) Table 61. North America Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 62. North America Live and Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 64. Europe Live and Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Live and Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 68. Latin America Live and Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Live and Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Sanofi Live and Attenuated Vaccine Product Portfolio Table 75. Sanofi Recent Development Table 76. Johnson & Johnson Company Information Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Johnson & Johnson Live and Attenuated Vaccine Product Portfolio Table 80. Johnson & Johnson Recent Development Table 81. Merck & Co. Company Information Table 82. Merck & Co. Business Overview Table 83. Merck & Co. Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Merck & Co. Live and Attenuated Vaccine Product Portfolio Table 85. Merck & Co. Recent Development Table 86. Pfizer, Inc Company Information Table 87. Pfizer, Inc Business Overview Table 88. Pfizer, Inc Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Pfizer, Inc Live and Attenuated Vaccine Product Portfolio Table 90. Pfizer, Inc Recent Development Table 91. GlaxoSmithKline Company Information Table 92. GlaxoSmithKline Business Overview Table 93. GlaxoSmithKline Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio Table 95. GlaxoSmithKline Recent Development Table 96. Serum Institute Company Information Table 97. Serum Institute Business Overview Table 98. Serum Institute Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Serum Institute Live and Attenuated Vaccine Product Portfolio Table 100. Serum Institute Recent Development Table 101. MedImmune, LLC Company Information Table 102. MedImmune, LLC Business Overview Table 103. MedImmune, LLC Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. MedImmune, LLC Live and Attenuated Vaccine Product Portfolio Table 105. MedImmune, LLC Recent Development Table 106. Emergent BioSolutions, Inc. Company Information Table 107. Emergent BioSolutions, Inc. Business Overview Table 108. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio Table 110. Emergent BioSolutions, Inc. Recent Development Table 111. CSL Limited Company Information Table 112. CSL Limited Business Overview Table 113. CSL Limited Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. CSL Limited Live and Attenuated Vaccine Product Portfolio Table 115. CSL Limited Recent Development Table 116. Astellas Pharma Inc Company Information Table 117. Astellas Pharma Inc Business Overview Table 118. Astellas Pharma Inc Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio Table 120. Astellas Pharma Inc Recent Development Table 121. North America Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 122. North America Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 123. North America Live and Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 124. North America Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 125. North America Live and Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 126. North America Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Live and Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Live and Attenuated Vaccine Market Share by Country (2021-2026) Table 129. North America Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Live and Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 131. Europe Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 132. Europe Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 133. Europe Live and Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 134. Europe Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 135. Europe Live and Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Live and Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Live and Attenuated Vaccine Market Share by Country (2021-2026) Table 139. Europe Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Live and Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 143. Asia-Pacific Live and Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 145. Asia-Pacific Live and Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Live and Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Live and Attenuated Vaccine Market Share by Country (2021-2026) Table 149. Asia-Pacific Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Live and Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 151. Latin America Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. Latin America Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 153. Latin America Live and Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 154. Latin America Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 155. Latin America Live and Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Live and Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Live and Attenuated Vaccine Market Share by Country (2021-2026) Table 159. Latin America Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Live and Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 163. Middle East and Africa Live and Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 165. Middle East and Africa Live and Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Live and Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Live and Attenuated Vaccine Market Share by Country (2021-2026) Table 169. Middle East and Africa Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Live and Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Live and Attenuated Vaccine Distributors List Table 174. Live and Attenuated Vaccine Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Live and Attenuated Vaccine Image Figure 2. Global Live and Attenuated Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live and Attenuated Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Live and Attenuated Vaccine Sales (2021-2032) & (k units) Figure 5. Pediatric Vaccine Image Figure 6. Global Pediatric Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 7. Adult Vaccines Image Figure 8. Global Adult Vaccines Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Live and Attenuated Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Live and Attenuated Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Live and Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Live and Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Live and Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Live and Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Live and Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Live and Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Live and Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Live and Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Live and Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Live and Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Live and Attenuated Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Clinics Image Figure 24. Global Clinics Sales YoY Growth (2021-2032) & (k units) Figure 25. Diagnostic Centers Image Figure 26. Global Diagnostic Centers Sales YoY Growth (2021-2032) & (k units) Figure 27. Hospitals Image Figure 28. Global Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 29. Research Institute Image Figure 30. Global Research Institute Sales YoY Growth (2021-2032) & (k units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Live and Attenuated Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Live and Attenuated Vaccine Market Share by Application 2025 VS 2032 Figure 35. North America Live and Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. North America Live and Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Europe Live and Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Europe Live and Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Live and Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Live and Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Latin America Live and Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Live and Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Live and Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Live and Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 45. North America Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Live and Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Live and Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Live and Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Live and Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Live and Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Live and Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Live and Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Live and Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Live and Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Live and Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Live and Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Live and Attenuated Vaccine Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Live and Attenuated Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric Vaccine
  • Adult Vaccines
Applications
  • Clinics
  • Diagnostic Centers
  • Hospitals
  • Research Institute
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer, Inc
  • GlaxoSmithKline
  • Serum Institute
  • MedImmune, LLC
  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Astellas Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live and Attenuated Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Live and Attenuated Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Live and Attenuated Vaccine Market by Type
  6. 1.3.1 Pediatric Vaccine
  7. 1.3.2 Adult Vaccines
  8. 1.4 Global Live and Attenuated Vaccine Market Size by Type
  9. 1.4.1 Global Live and Attenuated Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Live and Attenuated Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Live and Attenuated Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Live and Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Live and Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Live and Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Live and Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Live and Attenuated Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Live and Attenuated Vaccine Industry Trends
  2. 2.2 Live and Attenuated Vaccine Industry Drivers
  3. 2.3 Live and Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Live and Attenuated Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Live and Attenuated Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Live and Attenuated Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Live and Attenuated Vaccine Price (2021-2026)
  4. 3.4 Global Live and Attenuated Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live and Attenuated Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Live and Attenuated Vaccine Company, Product Type & Application
  7. 3.7 Global Live and Attenuated Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live and Attenuated Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live and Attenuated Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live and Attenuated Vaccine Tier 1, Tier 2, and Tier 3
4 Live and Attenuated Vaccine Regional Status and Outlook
  1. 4.1 Global Live and Attenuated Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Live and Attenuated Vaccine Historic Market Size by Region
  3. 4.2.1 Global Live and Attenuated Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Live and Attenuated Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Live and Attenuated Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Live and Attenuated Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Live and Attenuated Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Live and Attenuated Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Live and Attenuated Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Live and Attenuated Vaccine by Application
  1. 5.1 Live and Attenuated Vaccine Market by Application
  2. 5.1.1 Clinics
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Hospitals
  5. 5.1.4 Research Institute
  6. 5.1.5 Others
  7. 5.2 Global Live and Attenuated Vaccine Market Size by Application
  8. 5.2.1 Global Live and Attenuated Vaccine Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Live and Attenuated Vaccine Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Live and Attenuated Vaccine Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Live and Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Live and Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Live and Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Live and Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Live and Attenuated Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Live and Attenuated Vaccine Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Live and Attenuated Vaccine Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Merck & Co.
  14. 6.3.1 Merck & Co. Company Information
  15. 6.3.2 Merck & Co. Business Overview
  16. 6.3.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck & Co. Live and Attenuated Vaccine Product Portfolio
  18. 6.3.5 Merck & Co. Recent Developments
  19. 6.4 Pfizer, Inc
  20. 6.4.1 Pfizer, Inc Company Information
  21. 6.4.2 Pfizer, Inc Business Overview
  22. 6.4.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer, Inc Live and Attenuated Vaccine Product Portfolio
  24. 6.4.5 Pfizer, Inc Recent Developments
  25. 6.5 GlaxoSmithKline
  26. 6.5.1 GlaxoSmithKline Company Information
  27. 6.5.2 GlaxoSmithKline Business Overview
  28. 6.5.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio
  30. 6.5.5 GlaxoSmithKline Recent Developments
  31. 6.6 Serum Institute
  32. 6.6.1 Serum Institute Company Information
  33. 6.6.2 Serum Institute Business Overview
  34. 6.6.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Serum Institute Live and Attenuated Vaccine Product Portfolio
  36. 6.6.5 Serum Institute Recent Developments
  37. 6.7 MedImmune, LLC
  38. 6.7.1 MedImmune, LLC Company Information
  39. 6.7.2 MedImmune, LLC Business Overview
  40. 6.7.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 MedImmune, LLC Live and Attenuated Vaccine Product Portfolio
  42. 6.7.5 MedImmune, LLC Recent Developments
  43. 6.8 Emergent BioSolutions, Inc.
  44. 6.8.1 Emergent BioSolutions, Inc. Company Information
  45. 6.8.2 Emergent BioSolutions, Inc. Business Overview
  46. 6.8.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio
  48. 6.8.5 Emergent BioSolutions, Inc. Recent Developments
  49. 6.9 CSL Limited
  50. 6.9.1 CSL Limited Company Information
  51. 6.9.2 CSL Limited Business Overview
  52. 6.9.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 CSL Limited Live and Attenuated Vaccine Product Portfolio
  54. 6.9.5 CSL Limited Recent Developments
  55. 6.10 Astellas Pharma Inc
  56. 6.10.1 Astellas Pharma Inc Company Information
  57. 6.10.2 Astellas Pharma Inc Business Overview
  58. 6.10.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio
  60. 6.10.5 Astellas Pharma Inc Recent Developments
7 North America by Country
  1. 7.1 North America Live and Attenuated Vaccine Sales by Country
  2. 7.1.1 North America Live and Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Live and Attenuated Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Live and Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Live and Attenuated Vaccine Market Size by Country
  6. 7.2.1 North America Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Live and Attenuated Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Live and Attenuated Vaccine Sales by Country
  2. 8.1.1 Europe Live and Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Live and Attenuated Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Live and Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Live and Attenuated Vaccine Market Size by Country
  6. 8.2.1 Europe Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Live and Attenuated Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Live and Attenuated Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Live and Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Live and Attenuated Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Live and Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Live and Attenuated Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Live and Attenuated Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Live and Attenuated Vaccine Sales by Country
  2. 10.1.1 South America Live and Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Live and Attenuated Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Live and Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Live and Attenuated Vaccine Market Size by Country
  6. 10.2.1 South America Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Live and Attenuated Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Live and Attenuated Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Live and Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Live and Attenuated Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Live and Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Live and Attenuated Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Live and Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Live and Attenuated Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Live and Attenuated Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Live and Attenuated Vaccine Value Chain Analysis
  2. 12.1.1 Live and Attenuated Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Live and Attenuated Vaccine Production Mode & Process
  7. 12.2 Live and Attenuated Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Live and Attenuated Vaccine Distributors
  10. 12.2.3 Live and Attenuated Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst